Purpose: In 2022 the American Urological Association (AUA) requested an Update
Literature Review (ULR) to incorporate new evidence generated since the 2020 publication …

Context Identification of early nodal recurrence after primary prostate cancer (PCa) treatment
by functional imaging may guide metastasis-directed therapy such as salvage lymph node …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Background In a subset of patients with recurrent oligometastatic prostate cancer (PCa)
salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance …

Background Long-term outcomes of patients treated with salvage lymph node dissection
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

Background Prostate-specific membrane antigen (PSMA)-ligand positron emission
tomography (PET) allows detection of metastatic prostate cancer (PC) lesions at low prostate …

Simple Summary The combination of positron emission tomography (PET)-diagnostics with
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …

Background Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer
disease is diagnosed more often, leading to an increasing interest in metastasis-directed …

Oligometastatic prostate cancer (OMPC), generally defined by presence of five or fewer
metastatic sites on imaging, represents a transitional state between localized and …